Key result
SSRIs may reduce CHD risk in depressed patients by mitigating inflammation and metabolic dysregulation.
Why the study?
Do selective serotonin reuptake inhibitors (SSRIs) reduce coronary heart disease risk in patients with depression by mediating pathogenetic pathways?
Do selective serotonin reuptake inhibitors (SSRIs) reduce coronary heart disease risk in patients with depression by mediating pathogenetic pathways?
Answers are grounded in this paper and cite their sources.
SSRIs may reduce the risk of coronary heart disease in depressed patients by mitigating depression-induced inflammation and metabolic alterations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mathews et al. (2015) conducted a review in Depression and Coronary Heart Disease. Selective serotonin reuptake inhibitors (SSRIs) was evaluated. Selective serotonin reuptake inhibitors may reduce coronary heart disease risk in depressed patients by mediating the negative effects of depression on inflammation and metabolic dysregulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: